Specialist care for gestational trophoblastic neoplasia, with precise diagnosis and personalised treatment based on the type and extent of disease.
Gestational trophoblastic neoplasia can develop after a molar pregnancy and, in some cases, after a normal pregnancy, miscarriage or other pregnancy. A persistently raised or rising beta-hCG level may be an important sign that further evaluation is needed. Because these conditions are uncommon, assessment by a gynaecologic oncology specialist can help establish the diagnosis and determine the appropriate treatment plan.
Treatment depends on the type of GTN, disease extent and risk classification. Depending on the individual case, treatment may include chemotherapy, surgery or a combination of treatments. Dr. Priya Bhati provides specialist evaluation and surgical expertise as part of gynaecologic oncology care in Kochi.
Gestational trophoblastic neoplasia, commonly called GTN, refers to a group of rare pregnancy-related conditions in which abnormal trophoblastic cells continue to grow after a pregnancy.
Trophoblastic cells normally develop during pregnancy and form part of the placenta. In gestational trophoblastic disease, these cells grow abnormally. Some forms are non-cancerous, while others can behave like cancer and require active treatment.
GTN may develop after a molar pregnancy, but it can also occur after other types of pregnancy. The condition includes different diseases, such as invasive mole and choriocarcinoma. Rare forms include placental site trophoblastic tumour and epithelioid trophoblastic tumour.
The diagnosis and treatment are different from those of more common gynaecological cancers. This is one reason why specialist evaluation is important.
Gestational trophoblastic neoplasia develops from cells associated with pregnancy rather than from the usual tissues where cancers such as ovarian, cervical or endometrial cancer begin.
One of the most useful markers in these conditions is beta-human chorionic gonadotropin, or beta-hCG.
Beta-hCG is a hormone produced during pregnancy. After a pregnancy ends, the level normally falls over time. When trophoblastic tissue remains active, beta-hCG may stay elevated, stop falling as expected or begin to rise.
This makes beta-hCG an important part of diagnosis and follow-up.
However, one abnormal beta-hCG result does not automatically mean that a woman has GTN. The timing of the test, previous pregnancy, previous treatment and the pattern of beta-hCG levels all need to be considered.
GTN is most commonly associated with a previous molar pregnancy, but it is not limited to molar pregnancy.
It can develop following:
Some women may first become aware that something is wrong because their beta-hCG does not return to normal after pregnancy.
Others may have symptoms such as abnormal vaginal bleeding, an enlarged uterus or other symptoms that require further investigation.
Because GTN is uncommon and can present in different ways, the complete pregnancy and treatment history is important when assessing the condition.
A molar pregnancy is a type of gestational trophoblastic disease in which abnormal placental tissue develops.
There are two main types:
In a complete mole, abnormal trophoblastic tissue develops without a normal developing fetus.
In a partial mole, some fetal tissue may be present, but the pregnancy is not capable of developing normally.
Most molar pregnancies do not become malignant. However, some women develop persistent gestational trophoblastic disease after the pregnancy tissue has been removed.
This is why follow-up beta-hCG testing is so important after a molar pregnancy.
Beta-hCG monitoring is one of the most important parts of managing gestational trophoblastic disease.
After treatment of a molar pregnancy, the beta-hCG level is expected to fall. Doctors monitor the pattern over time rather than relying on a single test.
If beta-hCG remains elevated, stops falling as expected or rises again, further assessment may be required.
The pattern can help doctors determine whether pregnancy-related tissue is still present and whether the condition has progressed to GTN.
Regular follow-up is therefore not something to skip even if you feel completely well.
A woman may have very few symptoms while beta-hCG results are showing that further treatment is necessary.
Symptoms vary depending on the type of GTN and whether the disease has spread.
Possible symptoms include:
Some women are diagnosed primarily through abnormal beta-hCG follow-up rather than because of significant symptoms.
This is why scheduled follow-up after a molar pregnancy is so important.
If you have been told that your beta-hCG level is not falling as expected, it is worth discussing the result with a specialist rather than waiting for symptoms to appear.
Diagnosis begins with a detailed review of your pregnancy history, previous treatment and beta-hCG results.
Your doctor may review:
Further investigations may include imaging and other tests depending on your individual situation.
The aim is to determine whether persistent trophoblastic disease is present and, if so, identify the specific type and extent of disease.
Once GTN is diagnosed, doctors may use the FIGO staging and scoring system to assess the extent of disease and estimate treatment risk.
The score considers several clinical factors, which may include:
The resulting classification helps doctors decide which treatment approach is appropriate.
GTN is commonly divided into low-risk and high-risk disease based on the FIGO scoring system.
This distinction matters because low-risk and high-risk GTN are generally treated differently.
Low-risk GTN is usually treated with chemotherapy using a single anticancer medicine.
The specific drug and treatment schedule depend on the individual case and the treating team's protocol.
Treatment continues with close monitoring of beta-hCG levels.
The goal is to eliminate the abnormal trophoblastic cells and achieve a sustained normal beta-hCG level.
If the disease does not respond adequately to the initial medicine, another treatment approach may be required.
The important point is that treatment decisions are based on how the disease responds, not simply on the initial diagnosis.
High-risk GTN generally requires combination chemotherapy.
The treatment is more intensive because high-risk disease has a greater potential to spread or behave aggressively.
The treatment plan may involve several chemotherapy medicines given according to a carefully planned schedule.
Additional treatment may sometimes be considered if there is disease in particular organs or if a tumour remains after systemic treatment.
Management of high-risk GTN requires close coordination between specialists, particularly when there is disease outside the uterus.
Not every case of gestational trophoblastic disease requires chemotherapy.
A molar pregnancy without persistent GTN may be managed with removal of the pregnancy tissue followed by careful beta-hCG monitoring.
When GTN is diagnosed, chemotherapy is commonly the main treatment.
However, surgery can have an important role in selected situations.
The appropriate treatment depends on the type of GTN, disease stage, risk category, previous treatment and response to therapy.
This is why treatment should not be decided from a single scan or blood test alone.
Surgery is not the main treatment for every type of GTN, but it may be appropriate in selected patients.
Surgery can be considered when:
For some rare forms, such as placental site trophoblastic tumour, surgery may be a central part of treatment.
The decision depends heavily on the type and extent of disease.
Placental site trophoblastic tumour, or PSTT, is a rare form of gestational trophoblastic neoplasia.
It behaves differently from more common forms such as invasive mole and choriocarcinoma.
PSTT can produce lower levels of beta-hCG relative to the amount of disease, which means the diagnosis cannot always be assessed through beta-hCG alone.
Treatment is therefore planned according to the stage, tumour characteristics and individual patient factors.
When disease is confined to the uterus, surgery may play a major role. More advanced disease may require additional systemic treatment.
Because PSTT is rare, evaluation by a gynaecologic oncology team with experience in unusual trophoblastic tumours is particularly valuable.
Choriocarcinoma is a malignant form of gestational trophoblastic disease.
It can develop after different types of pregnancy and may spread through the bloodstream to organs such as the lungs.
Despite its serious nature, gestational trophoblastic tumours are often highly responsive to chemotherapy.
Treatment is selected according to the extent and risk classification of the disease.
If there is suspected spread to other organs, staging investigations are important before treatment begins.
Yes. Some forms of GTN can spread beyond the uterus.
The lungs are a common site of spread, but other organs may also be involved in advanced disease.
The possibility of spread is one reason staging investigations and risk assessment are important.
Treatment is not based only on where the original pregnancy occurred. Doctors need to understand the complete pattern of disease before deciding on the treatment plan.
The exact tests depend on your previous pregnancy, beta-hCG pattern, symptoms and suspected type of disease.
Your evaluation may include:
The purpose of these tests is not simply to confirm a diagnosis. They also help determine the stage and risk category so treatment can be planned appropriately.
Many forms of gestational trophoblastic neoplasia respond very well to treatment.
The prognosis depends on factors such as the type of disease, stage, risk category, previous treatment and response to therapy.
Low-risk GTN generally has very high cure rates with appropriate treatment, while high-risk disease requires more intensive management.
Even when treatment needs to be changed because the first chemotherapy does not work as expected, additional treatment options may be available.
For this reason, a diagnosis of GTN should not automatically be viewed as a hopeless situation.
It should, however, be taken seriously and treated under specialist supervision.
Treatment does not necessarily end when chemotherapy finishes.
Follow-up is an important part of GTN care.
Beta-hCG testing is used to confirm that the disease has responded completely and remains under control.
Your doctor will explain how frequently you need testing and how long follow-up should continue.
During this period, pregnancy is usually avoided because a new pregnancy causes beta-hCG levels to rise and can make monitoring difficult.
Your specialist can advise you about contraception and when it may be appropriate to plan a future pregnancy.
For many women, future pregnancy is possible after successful treatment for GTN.
However, the timing of pregnancy should be discussed with your treating team.
Follow-up needs to be completed according to the treatment plan before trying to conceive.
Your doctor may also discuss contraception during the follow-up period.
If preserving fertility is important to you, tell your doctor early in the treatment process. This allows fertility and reproductive concerns to be considered alongside cancer treatment.
Not necessarily.
The effect on fertility depends on the type and intensity of treatment, the specific medicines used, whether surgery is required and other individual factors.
Many women treated for GTN can have successful pregnancies later.
If fertility is a major concern, discuss it before treatment begins. Your doctor can explain how the proposed treatment may affect reproductive health and what options may be available.
GTN can occasionally recur after treatment.
A recurrence may be identified through rising beta-hCG levels during follow-up or through symptoms or imaging.
Treatment for recurrent GTN depends on what treatment was previously given and how the disease responds.
Doctors may use different chemotherapy medicines, combination chemotherapy or surgery in selected cases.
A recurrence does not mean that treatment options have ended. It means that the disease needs to be reassessed and a new treatment plan developed.
Gestational trophoblastic neoplasia is uncommon and differs from most other gynaecological cancers.
A gynaecologic oncologist is trained to manage cancers and complex conditions affecting the female reproductive system, including uncommon malignancies.
Specialist care can be particularly useful when:
The aim is to establish exactly what you are dealing with before deciding what treatment should come next.
Dr. Priya Bhati is an Associate Professor in Gynaecologic Oncology at Amrita Hospital, Kochi. She completed her MCh in Gynaecologic Oncology at Christian Medical College, Vellore, after postgraduate training in Obstetrics and Gynaecology and experience at PGIMER Chandigarh.
Her area of expertise includes gynaecologic cancer surgery, laparoscopic gynaecologic and oncology surgery, robotic-assisted surgery and complex gynaecological procedures.
Amrita Hospital's Gynaecologic Oncology Division lists gestational trophoblastic disease among the conditions managed by the department. The programme also provides multidisciplinary cancer care involving specialists from areas such as medical oncology, radiation oncology, radiology and pathology.
For a woman diagnosed with GTN, having access to specialist evaluation and coordinated cancer care can help ensure that the diagnosis, risk classification and treatment plan are reviewed carefully.
If you are coming for a consultation about GTN, bring as much of your previous medical information as possible.
Useful documents include:
A timeline of your pregnancy, diagnosis, treatment and beta-hCG results can also be helpful.
If you have been receiving treatment at another hospital, bringing your previous records can help the specialist understand what has already been done.
Consider a specialist consultation if you have been told that your beta-hCG remains elevated after a pregnancy or molar pregnancy.
You should also seek specialist evaluation if:
Early specialist assessment can help clarify what the test results mean and what needs to happen next.
1. What is gestational trophoblastic neoplasia?
Gestational trophoblastic neoplasia, or GTN, is a group of rare pregnancy-related conditions in which abnormal trophoblastic cells continue to grow after a pregnancy. It can develop after a molar pregnancy or other types of pregnancy.
2. Is gestational trophoblastic neoplasia cancer?
Some forms of GTN are malignant and behave like cancer. Others are classified differently but can still require treatment and close monitoring. The exact diagnosis determines how the condition is managed.
3. What causes gestational trophoblastic neoplasia?
GTN develops from abnormal trophoblastic tissue associated with pregnancy. It is not caused by something a woman did during pregnancy.
4. Can GTN happen after a normal pregnancy?
Yes. Although GTN is commonly associated with molar pregnancy, some forms can occur after a normal pregnancy, miscarriage or ectopic pregnancy.
5. Why is my beta-hCG still high after pregnancy?
Beta-hCG normally falls after pregnancy. If it remains elevated or begins rising, your doctor may investigate whether pregnancy-related tissue remains. Persistent elevation does not automatically mean cancer, so the pattern and clinical history need to be assessed.
6. Does every molar pregnancy become GTN?
No. Most molar pregnancies do not progress to GTN. However, follow-up beta-hCG testing is important because a small proportion of women develop persistent disease requiring treatment.
7. What is the treatment for GTN?
Treatment depends on the type and risk category. Chemotherapy is commonly used, while surgery may be appropriate in selected situations. Some patients require a combination of treatments.
8. Is chemotherapy always needed for GTN?
When true GTN is diagnosed, chemotherapy is commonly the main treatment. However, the specific treatment depends on the type and extent of disease.
9. What is low-risk GTN?
Low-risk GTN is disease that falls into a lower category according to the FIGO scoring system. It is commonly treated with single-agent chemotherapy.
10. What is high-risk GTN?
High-risk GTN has a higher FIGO risk score and generally requires combination chemotherapy. The treatment is more intensive and requires close specialist monitoring.
11. Can GTN spread to the lungs?
Yes. Some forms of GTN can spread through the bloodstream, with the lungs being a common site of metastasis. Staging investigations help determine whether the disease has spread.
12. Is surgery required for GTN?
Not every patient needs surgery. Chemotherapy is the main treatment for many forms of GTN. Surgery may be considered for selected tumour types, significant bleeding, resistant disease or specific residual tumours.
13. What is placental site trophoblastic tumour?
Placental site trophoblastic tumour, or PSTT, is a rare form of gestational trophoblastic neoplasia. It can behave differently from other forms of GTN, so treatment needs to be planned according to its specific characteristics and stage.
14. Can GTN be cured?
Many patients with GTN can be successfully treated, particularly when the condition is diagnosed and managed appropriately. Prognosis depends on the type, stage, risk category and response to treatment.
15. Can I have children after GTN treatment?
Many women can become pregnant after successful treatment for GTN. The appropriate timing depends on your treatment and follow-up plan, so pregnancy should be discussed with your treating specialist.
16. Does chemotherapy for GTN cause infertility?
Not necessarily. The effect on fertility depends on the treatment received and individual circumstances. Discuss fertility concerns before treatment so they can be considered during treatment planning.
17. Can GTN come back after treatment?
Recurrence is possible but uncommon. Follow-up beta-hCG testing is important because it can help detect disease activity early.
18. How long do I need beta-hCG follow-up?
The duration of follow-up depends on your diagnosis and treatment. Your specialist will advise you about the testing schedule and when it is appropriate to stop monitoring.
19. Should I avoid pregnancy during GTN follow-up?
Your doctor will usually recommend avoiding pregnancy during the period when beta-hCG is being monitored because pregnancy itself raises beta-hCG and can interfere with follow-up.
20. Can I get a second opinion for GTN?
Yes. A second opinion can be useful if you have been diagnosed with GTN, have been advised to start chemotherapy or have questions about surgery or future fertility.
21. Which specialist treats gestational trophoblastic neoplasia?
A gynaecologic oncologist can evaluate and manage GTN as part of a specialist cancer care team. Depending on the case, medical oncology, radiology, pathology and other specialists may also be involved.
22. Where can I consult for GTN treatment in Kochi?
Dr. Priya Bhati provides gynaecologic oncology care in Kochi and has expertise in gynaecologic cancer surgery and complex gynaecological conditions. Consult her if you have persistent beta-hCG, suspected GTN or an established diagnosis requiring specialist treatment planning.
MBBS, M. Ch. (Gynaecologic Oncology), MD (Obs & Gynae)
Senior Consultant - Gynae Oncologist and Robotic Surgeon, Department of Gynecologic Oncology, Amrita Institute of Medical Sciences, Kochi, Kerala
Dr. Priya Bhati is a Senior Consultant Gynae Oncologist and Robotic Surgeon at Amrita Institute of Medical Sciences, Kochi. She specialises in the treatment of gynaecological cancers and complex gynaecological conditions, with expertise in cancer surgery, robotic-assisted surgery and laparoscopic surgery. With years of experience at leading institutions such as CMC Vellore and PGIMER Chandigarh, she brings extensive surgical experience along with a caring and patient-focused approach.
Dr. Priya has completed her M.B.B.S. from Kasturba Medical College, Mangalore, M.D. in Obstetrics & Gynecology from Goa Medical College, and M.Ch. in Gynaecologic Oncology from Christian Medical College, Vellore. She treats women with different types of gynaecological cancers and also performs complex benign gynaecological surgeries and advanced procedures such as CRS and HIPEC.
She believes that every patient deserves to understand her condition and treatment clearly. Along with treating gynaecological cancers, Dr. Priya also focuses on prevention and early detection, including HPV vaccination and preventive gynaecologic care. Her goal is to provide personalised treatment while making patients and their families feel informed, comfortable and supported throughout their care.
I was very scared when I came to know about my cancer. Dr. Priya Bhati explained everything clearly and told me what we should do next. I am really thankful for her support.
Dr. Bhati is very patient and listens to all your doubts. She explained my reports in simple words and did not make me feel rushed. I felt much better after talking to her.
We met Dr. Priya Bhati for my mother’s treatment. She explained the surgery properly and answered all our questions. We felt that she really understood our concerns.
I was worried about having surgery, but Dr. Bhati explained the procedure and what to expect. She was very calm and supportive. I am happy that we consulted her.
Dr. Bhati gave us enough time during the consultation and explained the treatment options clearly. She also listened to what we wanted to know. Very good doctor and a very positive experience.
After my diagnosis, I was confused about what to do next. Dr. Bhati went through my reports and explained everything step by step. Her guidance gave me confidence to start my treatment.